HEADER HYDROLASE/HYDROLASE INHIBITOR 02-OCT-05 2C2Z TITLE CRYSTAL STRUCTURE OF CASPASE-8 IN COMPLEX WITH AZA-PEPTIDE MICHAEL TITLE 2 ACCEPTOR INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: CASPASE-8 P18 SUBUNIT; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: ALPHA SUB-UNIT, RESIDUES 218-374; COMPND 5 EC: 3.4.22.-; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: CASPASE-8 P10 SUBUNIT; COMPND 9 CHAIN: B; COMPND 10 FRAGMENT: BETA-SUBUNIT, RESIDUES 376-479; COMPND 11 EC: 3.4.22.-; COMPND 12 ENGINEERED: YES; COMPND 13 MOL_ID: 3; COMPND 14 MOLECULE: AZA-PEPTIDE INHIBITOR (5S, 8R, 11S)-8-(2-CARBOXYETHYL) COMPND 15 -14-[4-(3,4-DIHYDROQUINOLIN-1(2H)-YL)-4-OXOBUTANOYL] COMPND 16 -11-[(1R)-1-HYDROXYETHYL]-5-(2-METHYLPROPYL)-3,6,9,12-TETRAOXO COMPND 17 -1-PHENYL-2-OXA-4,7,10,13,14-PENTAAZAHEXADECAN-16-OIC ACID; COMPND 18 CHAIN: C; COMPND 19 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET11D; SOURCE 10 MOL_ID: 2; SOURCE 11 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 12 ORGANISM_COMMON: HUMAN; SOURCE 13 ORGANISM_TAXID: 9606; SOURCE 14 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 15 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 16 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 17 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 18 EXPRESSION_SYSTEM_PLASMID: PET11D; SOURCE 19 MOL_ID: 3; SOURCE 20 SYNTHETIC: YES; SOURCE 21 ORGANISM_SCIENTIFIC: SYNTHETIC CONSTRUCT; SOURCE 22 ORGANISM_TAXID: 32630 KEYWDS HYDROLASE-HYDROLASE INHIBITOR COMPLEX, APOPTOSIS, CYSTEINE-PROTEASE, KEYWDS 2 ICE, THIOL PROTEASE, ZYMOGEN, CPP32, YAMA, AZA-PEPTIDE, MICHAEL KEYWDS 3 ACCEPTOR, AZA-ASP, CLAN CD EXPDTA X-RAY DIFFRACTION AUTHOR R.GANESAN,S.JELAKOVIC,O.D.EKICI,Z.Z.LI,K.E.JAMES,J.L.ASGIAN, AUTHOR 2 A.J.CAMPBELL,J.MIKOLAJCZYK,G.S.SALVESEN,J.C.POWERS,M.G.GRUETTER REVDAT 5 08-FEB-17 2C2Z 1 SOURCE REVDAT 4 20-JUL-11 2C2Z 1 COMPND REVDAT REMARK REVDAT 3 13-JUL-11 2C2Z 1 VERSN REVDAT 2 24-FEB-09 2C2Z 1 VERSN REVDAT 1 20-SEP-06 2C2Z 0 JRNL AUTH O.D.EKICI,Z.Z.LI,A.J.CAMPBELL,K.E.JAMES,J.L.ASGIAN, JRNL AUTH 2 J.MIKOLAJCZYK,G.S.SALVESEN,R.GANESAN,S.JELAKOVIC, JRNL AUTH 3 M.G.GRUTTER,J.C.POWERS JRNL TITL DESIGN, SYNTHESIS, AND EVALUATION OF AZA-PEPTIDE MICHAEL JRNL TITL 2 ACCEPTORS AS SELECTIVE AND POTENT INHIBITORS OF CASPASES-2, JRNL TITL 3 -3, -6, -7, -8, -9, AND - 10. JRNL REF J.MED.CHEM. V. 49 5728 2006 JRNL REFN ISSN 0022-2623 JRNL PMID 16970398 JRNL DOI 10.1021/JM0601405 REMARK 2 REMARK 2 RESOLUTION. 1.95 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.95 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 2150768.420 REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.5 REMARK 3 NUMBER OF REFLECTIONS : 21815 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.171 REMARK 3 FREE R VALUE : 0.187 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.000 REMARK 3 FREE R VALUE TEST SET COUNT : 648 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.007 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.95 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.07 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 100.00 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 3473 REMARK 3 BIN R VALUE (WORKING SET) : 0.1800 REMARK 3 BIN FREE R VALUE : 0.1980 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 2.90 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 104 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.019 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1968 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 8 REMARK 3 SOLVENT ATOMS : 324 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 8.00 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 19.50 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 2.75000 REMARK 3 B22 (A**2) : 2.75000 REMARK 3 B33 (A**2) : -5.50000 REMARK 3 B12 (A**2) : -0.09000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.18 REMARK 3 ESD FROM SIGMAA (A) : 0.07 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.20 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.07 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.006 REMARK 3 BOND ANGLES (DEGREES) : 1.30 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 22.70 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.83 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.45 REMARK 3 BSOL : 63.50 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : DTD.PAR REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : DTD.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: MISSING RESIDUES A216-222, A372-374, REMARK 3 B374-389 REMARK 4 REMARK 4 2C2Z COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 03-OCT-05. REMARK 100 THE PDBE ID CODE IS EBI-25835. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 21-APR-05 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 8.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SLS REMARK 200 BEAMLINE : X06SA REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.90001 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 22937 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.920 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.9 REMARK 200 DATA REDUNDANCY : 7.800 REMARK 200 R MERGE (I) : 0.05000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 29.6100 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.92 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.02 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.6 REMARK 200 DATA REDUNDANCY IN SHELL : 7.55 REMARK 200 R MERGE FOR SHELL (I) : 0.09000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 20.380 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 48.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.36 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.4M SODIUM CITRATE, 100MM HEPES PH 8.0 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 31 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+2/3 REMARK 290 6555 -X,-X+Y,-Z+1/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 43.31333 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 86.62667 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 86.62667 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 43.31333 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: HEXAMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: HEXAMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, C, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 350 BIOMT2 2 -0.866025 0.500000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 43.31333 REMARK 400 REMARK 400 COMPOUND REMARK 400 THE INITIAL LIGAND USED IN THE EXPERIMENT WAS CBZ-LETAD-CH=CH-CO- REMARK 400 TETRAHYDROQUINOLINE. UPON REACTION, THE DOUBLE BOND OPENED UP AND REMARK 400 FORMED A COVALENT BOND BETWEEN ATOM C10 OF RESIDUE MX5 5 OF CHAIN C REMARK 400 AND ATOM SG OF CYS 360 OF CHAIN A. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 216 REMARK 465 GLY A 217 REMARK 465 GLU A 218 REMARK 465 SER A 219 REMARK 465 GLN A 220 REMARK 465 THR A 221 REMARK 465 LEU A 222 REMARK 465 THR A 373 REMARK 465 ASP A 374 REMARK 465 MET B 374 REMARK 465 ALA B 375 REMARK 465 GLU B 376 REMARK 465 GLU B 377 REMARK 465 GLN B 378 REMARK 465 PRO B 379 REMARK 465 TYR B 380 REMARK 465 LEU B 381 REMARK 465 GLU B 382 REMARK 465 MET B 383 REMARK 465 ASP B 384 REMARK 465 LEU B 385 REMARK 465 SER B 386 REMARK 465 SER B 387 REMARK 465 PRO B 388 REMARK 465 GLN B 389 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 372 CA C O CB CG CD OE1 REMARK 470 GLU A 372 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 286 79.98 46.66 REMARK 500 ASN B 408 -15.71 78.02 REMARK 500 GLU B 417 -31.95 -133.52 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2172 DISTANCE = 5.84 ANGSTROMS REMARK 525 HOH B2027 DISTANCE = 5.31 ANGSTROMS REMARK 525 HOH B2034 DISTANCE = 5.07 ANGSTROMS REMARK 525 HOH B2100 DISTANCE = 5.52 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE DTD B 1480 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN C OF AZA-PEPTIDE REMARK 800 INHIBITOR (5S,8R,11S)-8-(2-CARBOXYETHYL)-14-[4-(3,4- REMARK 800 DIHYDROQUINOLIN-1(2H)-YL)-4-OXOBUTANOYL]-11-[(1R)-1-HYDROXYETHYL] REMARK 800 -5-(2-METHYLPROPYL)-3,6,9,12-TETRAOXO-1-PHENYL-2-OXA-4,7,10,13, REMARK 800 14-PENTAAZAHEXADECAN-16-OIC ACID REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1F9E RELATED DB: PDB REMARK 900 CASPASE-8 SPECIFICITY PROBED AT SUBSITE S4 : REMARK 900 CRYSTALSTRUCTURE OF THE CASPASE-8-Z-DEVD -CHO REMARK 900 RELATED ID: 1I4E RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CASPASE-8/P35 COMPLEX REMARK 900 RELATED ID: 1QDU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE COMPLEX OF CASPASE -8 WITH THE REMARK 900 TRIPEPTIDE KETONE INHIBITOR ZEVD-DCBMK REMARK 900 RELATED ID: 1QTN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE COMPLEX OF CASPASE -8 WITH THE REMARK 900 TETRAPEPTIDE INHIBITOR ACE-IETD -ALDEHYDE REMARK 900 RELATED ID: 2FUN RELATED DB: PDB REMARK 900 ALTERNATIVE P35-CASPASE-8 COMPLEX DBREF 2C2Z A 216 217 PDB 2C2Z 2C2Z 216 217 DBREF 2C2Z A 218 374 UNP Q14790 CASP8_HUMAN 218 374 DBREF 2C2Z B 374 375 PDB 2C2Z 2C2Z 374 375 DBREF 2C2Z B 376 479 UNP Q14790 CASP8_HUMAN 376 479 DBREF 2C2Z C 1 5 PDB 2C2Z 2C2Z 1 5 SEQRES 1 A 159 MET GLY GLU SER GLN THR LEU ASP LYS VAL TYR GLN MET SEQRES 2 A 159 LYS SER LYS PRO ARG GLY TYR CYS LEU ILE ILE ASN ASN SEQRES 3 A 159 HIS ASN PHE ALA LYS ALA ARG GLU LYS VAL PRO LYS LEU SEQRES 4 A 159 HIS SER ILE ARG ASP ARG ASN GLY THR HIS LEU ASP ALA SEQRES 5 A 159 GLY ALA LEU THR THR THR PHE GLU GLU LEU HIS PHE GLU SEQRES 6 A 159 ILE LYS PRO HIS ASP ASP CYS THR VAL GLU GLN ILE TYR SEQRES 7 A 159 GLU ILE LEU LYS ILE TYR GLN LEU MET ASP HIS SER ASN SEQRES 8 A 159 MET ASP CYS PHE ILE CYS CYS ILE LEU SER HIS GLY ASP SEQRES 9 A 159 LYS GLY ILE ILE TYR GLY THR ASP GLY GLN GLU ALA PRO SEQRES 10 A 159 ILE TYR GLU LEU THR SER GLN PHE THR GLY LEU LYS CYS SEQRES 11 A 159 PRO SER LEU ALA GLY LYS PRO LYS VAL PHE PHE ILE GLN SEQRES 12 A 159 ALA CYS GLN GLY ASP ASN TYR GLN LYS GLY ILE PRO VAL SEQRES 13 A 159 GLU THR ASP SEQRES 1 B 106 MET ALA GLU GLU GLN PRO TYR LEU GLU MET ASP LEU SER SEQRES 2 B 106 SER PRO GLN THR ARG TYR ILE PRO ASP GLU ALA ASP PHE SEQRES 3 B 106 LEU LEU GLY MET ALA THR VAL ASN ASN CYS VAL SER TYR SEQRES 4 B 106 ARG ASN PRO ALA GLU GLY THR TRP TYR ILE GLN SER LEU SEQRES 5 B 106 CYS GLN SER LEU ARG GLU ARG CYS PRO ARG GLY ASP ASP SEQRES 6 B 106 ILE LEU THR ILE LEU THR GLU VAL ASN TYR GLU VAL SER SEQRES 7 B 106 ASN LYS ASP ASP LYS LYS ASN MET GLY LYS GLN MET PRO SEQRES 8 B 106 GLN PRO THR PHE THR LEU ARG LYS LYS LEU VAL PHE PRO SEQRES 9 B 106 SER ASP SEQRES 1 C 5 PHQ LEU GLU THR MX5 HET PHQ C 1 10 HET MX5 C 5 22 HET DTD B1480 8 HETNAM PHQ BENZYL CHLOROCARBONATE HETNAM MX5 {1-[4-(3,4-DIHYDROQUINOLIN-1(2H)-YL)-4- HETNAM 2 MX5 OXOBUTANOYL]HYDRAZINO}ACETIC ACID HETNAM DTD DITHIANE DIOL HETSYN MX5 {N-[(E)-4-(3,4-DIHYDRO-2H-QUINOLIN-1-YL)-4-OXO-BUT-2- HETSYN 2 MX5 ENOYL]-HYDRAZINO}-ACETIC ACID FORMUL 3 PHQ C8 H7 CL O2 FORMUL 3 MX5 C15 H19 N3 O4 FORMUL 4 DTD C4 H8 O2 S2 FORMUL 5 HOH *324(H2 O) HELIX 1 1 PHE A 244 VAL A 251 1 8 HELIX 2 2 PRO A 252 HIS A 255 5 4 HELIX 3 3 GLY A 262 LEU A 277 1 16 HELIX 4 4 THR A 288 MET A 302 1 15 HELIX 5 5 ILE A 333 SER A 338 1 6 HELIX 6 6 GLN A 339 THR A 341 5 3 HELIX 7 7 CYS A 345 ALA A 349 5 5 HELIX 8 8 TRP B 420 CYS B 433 1 14 HELIX 9 9 PRO B 434 GLY B 436 5 3 HELIX 10 10 ASP B 438 ASN B 452 1 15 HELIX 11 11 LYS B 456 MET B 459 5 4 SHEET 1 AA 6 GLU A 280 ASP A 285 0 SHEET 2 AA 6 TYR A 235 ASN A 240 1 O CYS A 236 N LYS A 282 SHEET 3 AA 6 PHE A 310 LEU A 315 1 O ILE A 311 N LEU A 237 SHEET 4 AA 6 LYS A 353 GLN A 358 1 O VAL A 354 N CYS A 312 SHEET 5 AA 6 PHE B 399 MET B 403 1 O LEU B 400 N PHE A 355 SHEET 6 AA 6 GLN B 465 PHE B 468 -1 O GLN B 465 N MET B 403 SHEET 1 AB 3 GLY A 318 ASP A 319 0 SHEET 2 AB 3 ILE A 322 TYR A 324 -1 O ILE A 322 N ASP A 319 SHEET 3 AB 3 GLU A 330 PRO A 332 -1 O ALA A 331 N ILE A 323 SHEET 1 BA 2 ARG B 413 ASN B 414 0 SHEET 2 BA 2 GLY B 418 THR B 419 -1 O GLY B 418 N ASN B 414 LINK C1 PHQ C 1 N LEU C 2 1555 1555 1.32 LINK C THR C 4 N20 MX5 C 5 1555 1555 1.31 LINK SG CYS A 360 C10 MX5 C 5 1555 1555 1.87 CISPEP 1 LYS A 231 PRO A 232 0 0.13 SITE 1 AC1 10 TYR A 334 THR A 337 HOH A2168 GLU B 396 SITE 2 AC1 10 PHE B 399 LEU B 401 GLN B 465 THR B 469 SITE 3 AC1 10 HOH B2103 HOH B2104 SITE 1 AC2 28 LEU A 254 ARG A 260 SER A 316 HIS A 317 SITE 2 AC2 28 GLY A 318 TYR A 324 LEU A 343 LYS A 344 SITE 3 AC2 28 GLN A 358 ALA A 359 CYS A 360 HOH A2051 SITE 4 AC2 28 SER B 411 TYR B 412 ARG B 413 ASN B 414 SITE 5 AC2 28 PRO B 415 ALA B 416 THR B 419 TRP B 420 SITE 6 AC2 28 HOH B2037 HOH C2216 HOH C2217 HOH C2218 SITE 7 AC2 28 HOH C2220 HOH C2221 HOH C2222 HOH C2224 CRYST1 62.520 62.520 129.940 90.00 90.00 120.00 P 31 2 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015995 0.009235 0.000000 0.00000 SCALE2 0.000000 0.018469 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007696 0.00000